Please login to the form below

Not currently logged in
Email:
Password:

PAH

This page shows the latest PAH news and features for those working in and with pharma, biotech and healthcare.

GSK and Novartis lead at PM Society Digital Awards

GSK and Novartis lead at PM Society Digital Awards

GSK’s My PAH mobile app by the EarthWorks and its ERS meeting by ebee Health were rewarded, as were Novartis’COPD life is calling by Health Unlimited and the HACk – ... Healthcare Partnerships. My PAH by the EarthWorks. Patient initiatives. PRIME

Latest news

More from news
Approximately 5 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • Six degrees of participation Six degrees of participation

    For example, our recent work to design a patient and carer mobile application for PAH has benefited from ongoing collaboration with clinicians, patient advocacy groups and leading tertiary centres across the

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck &Co grew cardiovascular revenues by 130%, while GSK enjoyed a 214% uplift, mainly due to its PAH treatment Volibris.

  • Pharma deals in September 2015 Pharma deals in September 2015

    In an attempt to be hunter rather than hunted, and to diversify its portfolio from just PAH (pulmonary arterial hypertension), Actelion has acknowledged it is holding “ preliminary discussions with ZS Pharma”. ... complement Actelion's PAH portfolio.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag). ... strong long-term growth potential to achieve leading positions in

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics